<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777892</url>
  </required_header>
  <id_info>
    <org_study_id>Pulmonic S3</org_study_id>
    <nct_id>NCT02777892</nct_id>
  </id_info>
  <brief_title>Pulmonic SAPIEN S3™ THV Registry</brief_title>
  <acronym>PulmonicS3</acronym>
  <official_title>Pulmonic SAPIEN S3™ THV Registry A Multi-center, Observational Registry With Retrospective Enrollment of Patients That Underwent Transcatheter Pulmonic Valve Implantation and a Retrospective or Prospective Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, Observational Registry with Retrospective Enrollment and Prospective Follow-up.

      The aim of the registry is to document the feasibility and safety of implanting an Edwards
      SAPIEN S3 transcatheter heart valve in the pulmonic position
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A malfunction or dysplasia of the pulmonary valve or the right ventricular outflow tract
      (RVOT) is one of the major components of the cardiac physiology in many congenital heart
      defects. Surgical correction of complex heart defects often includes some form of surgical
      repair or replacement of the native RVOT by biological valves such as homograft,
      bioprosthesis or Xenografts (i.e., Contegra conduits). Typical examples are tetralogy of
      Fallot (TOF) or double outlet right ventricle (DORV), pulmonary stenosis (PS), pulmonary
      atresia (PA), truncus arteriosus (TA), transposition of the great arteries (TGA) with PS
      (Rastelli's operation), absent pulmonary valve syndrome (Miller-Lev-Paul), Ross surgery for
      aortic valve disease and others. The repaired or replaced pulmonary valve however often
      becomes dysfunctional later on and many patients require surgical revisions of the RVOT with
      pulmonary valve replacement within 10 years of primary intervention.

      TPVI provides a less invasive alternative to surgery in patients with right
      ventricular-to-pulmonary artery (RV-PA) conduit dysfunction. Early results of percutaneous
      pulmonary valve implantation (PPVI) showed that it is a promising procedure compared to a
      conventional surgical intervention. Meanwhile, pre-stenting of the RVOT before PPVI is
      routinely performed, enabling PPVI in various anatomies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>changes in right ventricular and pulmonary artery pressure</measure>
    <time_frame>from baseline to 30 days after implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Max. flow velocity RVOT</measure>
    <time_frame>30 days after implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NYHA class</measure>
    <time_frame>from baseline to 30 days after implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in degree of pulmonary regurgitation</measure>
    <time_frame>from baseline to 30 days after implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospitalization</measure>
    <time_frame>30 days after implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Peak Oxygen consumption</measure>
    <time_frame>from baseline to 24 months after implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of cases with proper device function</measure>
    <time_frame>24 months after implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of structural valve Deterioration including stent fracture</measure>
    <time_frame>24 months after implantation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Valve Malfunction</condition>
  <condition>Right Ventricular Outflow Tract (RVOT) Dysfunction</condition>
  <arm_group>
    <arm_group_label>pulmonary valve replacement</arm_group_label>
    <description>SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sapien S3</intervention_name>
    <description>Patients that have undergone percutaneous implantation of an Edwards SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection</description>
    <arm_group_label>pulmonary valve replacement</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT
        Transcatheter Heart Valve in the pulmonic position at the time of data collection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Clinical indication and decision for the implantation of an Edwards SAPIEN 3 THV made

          -  Data release form

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bramlage, Prof MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut für Pharmakologie und Präventive Medizin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Bramlage, Prof MD</last_name>
    <phone>+49(0)4471850</phone>
    <phone_ext>3331</phone_ext>
    <email>peter.bramlage@ippmed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Gansz</last_name>
    <phone>+49(0)4471850</phone>
    <phone_ext>3335</phone_ext>
    <email>andrea.gansz@ippmed.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Pauls Hospital Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ron Carere, MD</last_name>
      <email>rcarere@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Ron Carere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Ewert, MD PD</last_name>
      <phone>+49 89 12183011</phone>
      <email>ewert@dhm.mhn.de</email>
    </contact>
    <contact_backup>
      <last_name>Ewert</last_name>
    </contact_backup>
    <investigator>
      <last_name>Peter Ewert, MD PD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzchirurgische Klinik und Poliklinik LMU</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaus Haas, MD</last_name>
      <email>nikolaus.haas@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Nikolaus Haas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oliver Kretschmar, MD</last_name>
      <email>oliver.kretschmar@kispi.uzh.ch</email>
    </contact>
    <investigator>
      <last_name>Oliver Kretschmar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

